Valuation: Alumis Inc.

Capitalization 283M 270M 255M 225M 402M 24.56B 446M 3.03B 1.12B 10.27B 1.06B 1.04B 43.1B P/E ratio 2024 *
-0.6x
P/E ratio 2025 * -1.31x
Enterprise value 163M 155M 146M 129M 231M 14.11B 256M 1.74B 645M 5.9B 611M 598M 24.77B EV / Sales 2024 *
-
EV / Sales 2025 * -
Free-Float
85.75%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+2.16%
1 week-8.11%
Current month-30.35%
1 month-31.81%
3 months-44.63%
6 months-59.01%
Current year-33.72%
More quotes
1 week
4.74
Extreme 4.74
5.75
1 month
4.74
Extreme 4.74
7.89
Current year
4.74
Extreme 4.74
9.07
1 year
4.74
Extreme 4.74
13.53
3 years
4.74
Extreme 4.74
13.53
5 years
4.74
Extreme 4.74
13.53
10 years
4.74
Extreme 4.74
13.53
More quotes
Director TitleAgeSince
Chief Executive Officer 60 2021-09-22
Director of Finance/CFO 60 2022-04-30
Chief Tech/Sci/R&D Officer 54 2022-08-31
Manager TitleAgeSince
Director/Board Member 60 2021-04-30
Director/Board Member 59 2021-05-31
Chairman 60 2021-09-22
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi.($)
+2.16%-8.11% - - 283M
-0.77%-2.20%+9.84%+98.50% 118B
-0.10%-5.13%-28.93%+8.03% 72.09B
-2.13%-3.83%+68.23%+140.90% 38.79B
-2.40%+1.89%+31.02%-22.46% 28.73B
+2.38%+3.29%+58.26%+12.45% 24.63B
+4.61%+2.25%+11.97%-30.27% 23.61B
-2.06%+6.27%+380.22%+952.71% 15.76B
+0.81%-0.80%+189.03%+244.83% 14.19B
+0.94%+8.59%-19.89%-31.61% 13.46B
Average +0.34%+0.15%+77.75%+152.57% 34.94B
Weighted average by Cap. -0.26%-1.16%+36.48%+99.29%
See all sector performances

Financials

2024 *2025 *
Net sales - -
Net income -276M -263M -248M -219M -392M -23.94B -434M -2.95B -1.09B -10.01B -1.04B -1.02B -42.02B -298M -284M -268M -236M -422M -25.82B -469M -3.19B -1.18B -10.8B -1.12B -1.09B -45.33B
Net Debt -121M -115M -108M -95.62M -171M -10.45B -190M -1.29B -478M -4.37B -452M -443M -18.34B 58.39M 55.59M 52.43M 46.31M 82.73M 5.06B 91.8M 624M 231M 2.12B 219M 214M 8.88B
More financial data * Estimated data
Logo Alumis Inc.
Alumis Inc. is a clinical-stage biopharmaceutical company. It develops two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that it is developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. It builds a pipeline of molecules with the potential to address a range of immune-mediated diseases as monotherapy or combination therapies. ESK-001 is an allosteric TYK2 inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus and Uveitis. A-005 as a CNS-penetrant, allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a range of neuroinflammatory and neurodegenerative diseases. It has several early-stage discovery assets, such as targets identified by its data analytics platform, for the potential treatment of immune-mediated indications. Its data analytics demonstrate a genetic rationale for TYK2 inhibition in diseases of the CNS.
Employees
146
More about the company
Date Price Change Volume
25-02-14 5.210 $ +2.16% 115,186
25-02-13 5.100 $ +1.39% 164,348
25-02-12 5.030 $ +0.40% 166,115
25-02-11 5.010 $ +3.94% 390,297
25-02-10 4.820 $ -14.99% 425,252

Delayed Quote Nasdaq, February 14, 2025 at 04:00 pm EST

More quotes
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
5.210USD
Average target price
22.75USD
Spread / Average Target
+336.66%
Consensus

Quarterly revenue - Rate of surprise